Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that data on REL-1017, its lead product candidate, will be showcased in two poster presentations at the CPDD 83rd Annual Meeting from June 21 to June 24, 2021. Both presentations, scheduled for June 21, 2021, will detail findings from studies demonstrating that REL-1017 showed no reinforcing properties compared to oxycodone and exhibited no withdrawal effects or physical dependence. REL-1017 is an NMDA receptor channel blocker in late-stage development as a treatment for major depressive disorder (MDD).

NEW YORK, June 15, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations at the College on Problems of Drug Dependence (CPDD) 83^rd Annual Meeting, which will be held virtually between June 21 through June 24, 2021.

Both presentations will take place on June 21, 2021, from 3:00 – 4:00 PM ET, during Session I.  Additional details are provided below:

Title: REL-1017 (esmethadone) Showed No Reinforcing Properties Compared to Oxycodone in Rat Self-Administration Study
Poster Number: M56

Title: REL-1017 (esmethadone) Demonstrates No Withdrawal Effects or Evidence of Physical Dependence in a Rat Study
Poster Number: M63

About REL-1017

REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.

About Relmada Therapeutics, Inc. 

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

 Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com

Media Inquiries:
FischTank PR
Relmada@FischTankPR.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-data-at-the-college-on-problems-of-drug-dependence-83rd-annual-scientific-meeting-301312360.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What is the focus of Relmada Therapeutics, Inc. and its product REL-1017?

Relmada Therapeutics, Inc. focuses on treating diseases of the central nervous system, particularly major depressive disorder (MDD). REL-1017 is a novel NMDA receptor channel blocker aimed at providing rapid-acting treatment for MDD.

When will the data related to REL-1017 be presented?

Data on REL-1017 will be presented at the College on Problems of Drug Dependence (CPDD) 83rd Annual Meeting, scheduled from June 21 through June 24, 2021.

What are the results of the studies presented on REL-1017?

The studies show that REL-1017 demonstrated no reinforcing properties compared to oxycodone and showed no withdrawal effects or evidence of physical dependence in rat studies.

What is the significance of the findings on REL-1017?

The findings indicate the potential of REL-1017 as a safer alternative for treating MDD, given its lack of reinforcing properties and withdrawal symptoms.

What is the current status of REL-1017's development?

REL-1017 is currently in late-stage development as an adjunctive treatment for major depressive disorder and has received Fast Track designation from the FDA.